Abstract: A protector includes a tubular part, a covering part, and a support part. The tubular part is formed around an axis in a tubular shape, locked to a headrest stay formed in a tubular shape in a state where the tubular part is inserted into the inside of the headrest stay, and into which a wiring material is inserted. The covering part is provided on one side of the tubular part in an axial direction along the axis, placed outside the headrest stay, and covers a tip end of the headrest stay in the axial direction.

Abstract: The present invention provides novel Compound (1) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, and medical uses thereof.

Abstract: Task of the present invention is to provide a tackifier solution having high solution stability and also provide, by using such a tackifier solution, a pellicle having only few tackifier residues and exhibiting reduced outgas generation. Present invention is a pellicle comprising a pellicle frame, a pellicle membrane stretched over an end surface of one opening of the pellicle frame, and a tackifier layer provided on an end surface of the other opening of the pellicle frame, wherein the tackifier layer contains a (meth)acrylic tackifier which is a solidified resin composition comprising a polymer (A) and a radical polymerization initiator (B), the polymer (A) having a structural unit derived from a (meth)acrylate and a side chain consisting of a carbon-carbon multiple bond-containing group.

Abstract: A pellicle includes: a pellicle frame; a pellicle film supported at one end surface of the pellicle frame; and an adhesive layer provided at another end surface of the pellicle frame. The adhesive layer has a swelling degree, which is represented by the following Equation (A), of 200% or lower. Equation (A): [post-immersion mass of 10-mg test piece collected from the adhesive layer/10 mg]×100. In Equation (A), the post-immersion mass represents a mass of the test piece after a 6-hour immersion of the test piece in 10 ml of a decane solution having a capillary column GC concentration of 99.0% or higher.

Abstract: The present disclosure provides a pellicle that includes: a pellicle frame; a pellicle film supported at one end surface of the pellicle frame; and an adhesive layer provided at another end surface of the pellicle frame, and satisfies the following Equation (1): [A60° C.]?4.0 gf/mm2 (1). In Equation (1), [A60° C.] represents a first peel strength when the pellicle is used in a test laminated body. The test laminated body is obtained by placing the pellicle on a quartz glass substrate such that the adhesive layer is in contact with a surface of the quartz glass substrate, and maintaining a load on the pellicle under prescribed conditions. The first peel strength represents a load per unit adhesion area, which load is required for peeling the pellicle included in the test laminated body from the quartz glass substrate using a standard universal tester under prescribed conditions.

Abstract: The present invention provides novel compounds (e.g., compounds of Formulae (I), (II), (III), (IV)) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or pharmaceutically acceptable salts thereof, optionally in a pharmaceutically acceptable carrier, and a medical uses thereof.

Abstract: In the optical transmission system (1), a variable ATT (40) is used to attenuate both a data optical signal (L1) and an OSC optical signal (27) passing through a section according to an ATT value. A monitoring control server (50) includes an input unit (51) for receiving an input of information for specifying a monitoring section in the optical transmission system (1), an information collection unit (52) for collecting information for calculating an ATT value from a transmission device (20) and the variable ATT (40) existing in the monitoring section, and a change trial unit (54) for executing first determination processing for determining whether both of the optical signals can be transmitted, in accordance with whether or not power at the time of receiving the both optical signals passing through the monitoring section falls within a prescribed range, based on the information collected by the information collection unit (52).

Abstract: Provided is a vibration reduction device for stator vanes (30) positioned behind rotor blades (28) in a turbo machine, comprising an annular base member (80) having a cylindrical shape concentric around a central axis of the casing and supporting base ends of the stator vanes which extend radially inward from an inner circumferential surface of the base member, an elastomeric damping member (100) surrounding and in slidable contact with an outer circumferential surface of the base member, and a preloading member (102) surrounding an outer circumferential surface of the elastomeric damping member and configured to apply a preload directed radially inward to the elastomeric damping member.

Abstract: An inter-transmission device connection registration device 30A includes a storage unit 31 that registers connection information of a case where transponders 12a to 13n and photo couplers 14a to 14n as divided various transmission devices are connected through a port o and a port i, a light emission instruction unit 33 that provides a light emission instruction to the subordinately connected transponders, a transmission/reception detection unit 34 configured to detect a light transmission and a light reception at opposing ports o and i1 between transmission devices, e.g., the transponder 12a and the photo coupler 14 in accordance with the light emission instruction, and a registration control unit 35 that performs a control of registering, in the storage unit 31, connection information W2a of the port o on a light transmission side and the port i1 on a light reception side that are detected.

Abstract: The present invention provides novel Compound (1) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, and medical uses thereof.

Abstract: The present invention provides novel compounds (e.g., compounds of Formulae (I), (II), (III), (IV)) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or pharmaceutically acceptable salts thereof, optionally in a pharmaceutically acceptable carrier, and a medical uses thereof.

Abstract: An oxygen concentration meter includes a zirconia sensor, a resistor, a constant-current circuit, a resistance detection section, and an oxygen concentration detection section. The resistor is connected in parallel to the zirconia sensor. The constant-current circuit is connected in parallel to the zirconia sensor and the resistor, and supplies an electric current. The resistance detection section detects the resistance of the zirconia sensor on the basis of the voltage of the zirconia sensor in accordance with the supplied electric current. The oxygen concentration detection section detects the oxygen concentration of gas to be measured that is supplied to the zirconia sensor, on the basis of the voltage of the zirconia sensor resulting from an oxygen concentration difference between the gas to be measured and reference gas.

Abstract: The present invention provides novel Compound (1) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, and medical uses thereof.

Abstract: Provided is a vibration reduction device for stator vanes (30) positioned behind rotor blades (28) in a turbo machine, comprising an annular base member (80) having a cylindrical shape concentric around a central axis of the casing and supporting base ends of the stator vanes which extend radially inward from an inner circumferential surface of the base member, an elastomeric damping member (100) surrounding and in slidable contact with an outer circumferential surface of the base member, and a preloading member (102) surrounding an outer circumferential surface of the elastomeric damping member and configured to apply a preload directed radially inward to the elastomeric damping member.

Abstract: An optical transmission system (10) includes a plurality of transmission devices such as transponders (TPs) and optical cross-connects (OXCs) installed in each of stations (11-15) connected via a communication network, a control device (20), and a substitute OXC (502) serving as a substitute transmission device. The control device 20 is installed in a control station (14) of the stations. The control device (20) controls the transmission devices of the stations (11-15) in a centralized manner in accordance with physical network (NW) configuration information (20D) stored in a DB (21) and including config information. When a transmission device is replaced with a new OXC (5o3) serving as a new transmission device, the substitute OXC (5o2) operates as a substitute for the new OXC (5o3) to communicate with the control device (20) until config setting necessary for the new OXC (5o3) is completed.

Abstract: The purpose of the present disclosure is to provide a pellicle that has an adhesive layer having good flatness, and a method for producing the pellicle with good reproducibility. Said purpose is achieved by a pellicle having: a pellicle frame; a pellicle film provided so as to be stretched on one end surface of the pellicle frame; and an adhesive layer provided on the other end surface of the pellicle frame. The adhesive layer contains a cured product of a resin composition containing a curable polymer (A), and a curing agent (B1) and a curing agent (B2). The curing agent (B1) and the curing agent (B2) have different curing conditions.

Abstract: An inter-transmission device connection registration device 30A includes a storage unit 31 that registers connection information of a case where transponders 12a to 13n and photo couplers 14a to 14n as divided various transmission devices are connected through a port o and a port i, a light emission instruction unit 33 that provides a light emission instruction to the subordinately connected transponders, a transmission/reception detection unit 34 configured to detect a light transmission and a light reception at opposing ports o and i1 between transmission devices, e.g., the transponder 12a and the photo coupler 14 in accordance with the light emission instruction, and a registration control unit 35 that performs a control of registering, in the storage unit 31, connection information W2a of the port o on a light transmission side and the port i1 on a light reception side that are detected.

Abstract: The present invention provides novel compounds (e.g., compounds of Formulae (I), (II), (III), (IV)) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or pharmaceutically acceptable salts thereof, optionally in a pharmaceutically acceptable carrier, and a medical uses thereof.

Abstract: An oxygen concentration meter includes a zirconia sensor, a resistor, a constant-current circuit, a resistance detection section, and an oxygen concentration detection section. The resistor is connected in parallel to the zirconia sensor. The constant-current circuit is connected in parallel to the zirconia sensor and the resistor, and supplies an electric current. The resistance detection section detects the resistance of the zirconia sensor on the basis of the voltage of the zirconia sensor in accordance with the supplied electric current. The oxygen concentration detection section detects the oxygen concentration of gas to be measured that is supplied to the zirconia sensor, on the basis of the voltage of the zirconia sensor resulting from an oxygen concentration difference between the gas to be measured and reference gas.

Abstract: The present invention provides novel compounds (e.g., compounds of Formulae (I), (II), (III), (IV)) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or pharmaceutically acceptable salts thereof, optionally in a pharmaceutically acceptable carrier, and a medical uses thereof.